Here are the 424B prospectus supplements from Structure Therapeutics Inc. (GPCR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPCR filings page.
GPCR amended its at-the-market program to permit up to $400,000,000 of American Depositary Shares (ADSs), each representing three ordinary shares, under an amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The prospectus supplement states ~$58.5 million (3,040,000 ADSs) were sold to date and the remaining capacity is $341,478,784. The sales agents may sell ADSs at market prices and receive commissions of up to 3.0% of gross proceeds. The last reported sale price was $40.84 per ADS on Nasdaq.